Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

Sun exposure, vitamin D and pancreatic cancer risk

High levels of ultraviolet radiation at an individual's birth location, sun-sensitive skin type and a history of skin cancer each decreased risk for pancreatic cancer, according to study results presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, held here June 18-21.

20 Jun 2012

Combination therapy may help defeat pancreatic cancer

Combining a new targeted therapy with standard chemotherapy may help defeat pancreatic cancer, according to results presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, held here June 18-21.

20 Jun 2012

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies

FORMA Therapeutics and TGen Drug Development (TD2) today announced an agreement to jointly develop transformative cancer therapies, leveraging the synergistic capabilities of both organizations.

19 Jun 2012

TGen, Scottsdale Healthcare open INNO-206 Phase 2 trial for pancreatic cancer

An investigational drug that acts like a Trojan Horse to deliver cancer killing agents for pancreatic cancer is being studied at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen) that treats cancer patients with promising new drugs.

15 Jun 2012

Prior chemotherapy extends postpalliative survival in pancreatic cancer

Patients with locally advanced pancreatic cancer have a more favorable prognosis after palliative chemoradiotherapy if they have previously been treated with a gemcitabine-based therapy, say Danish researchers.

14 Jun 2012

Azaya announces final results from ATI-1123 Phase I study on cancers

Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.

14 Jun 2012

Study reveals mystery of how pancreatic cancer escapes immune detection

Researchers at NYU School of Medicine have made a key discovery that could help doctors treat one of the deadliest cancers.

12 Jun 2012

Patients with type 2 diabetes have 20% increased risk of blood cancers

Patients with type 2 diabetes have a 20 percent increased risk of developing blood cancers, such as non-Hodgkin lymphoma, leukemia and myeloma, according to a new meta-analysis led by researchers at The Miriam Hospital.

6 Jun 2012

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.

5 Jun 2012

Antisense Pharma presents data from trabedersen Phase I/II cancer study at ASCO 2012

The biopharmaceutical company Antisense Pharma today presents trabedersen complete data from its clinical Phase I/II study in patients with advanced pancreatic cancer, malignant melanoma or colorectal cancer at the international cancer congress ASCO 2012 in Chicago, USA.

5 Jun 2012

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. today announced interim data from a phase I clinical trial evaluating ASG-5ME for the treatment of castration-resistant prostate cancer.

5 Jun 2012

New data from OncoMed’s OMP-59R5 Phase I study on advanced solid tumors

OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor initiating cells, today highlighted new data presented this afternoon in a poster discussion session at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL.

4 Jun 2012

Favorable results from CytRx’s INNO-206 Phase 1b/2 trial on soft tissue sarcomas

CytRx Corporation, a biopharmaceutical company specializing in oncology, announces that favorable clinical results from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate INNO-206 in patients with advanced solid tumors, primarily soft tissue sarcomas, are being presented today at the American Society of Clinical Oncology (ASCO) conference in Chicago.

4 Jun 2012

'Atzelberg Circle' researchers meet to advance hyperthermia as standard combination cancer therapy

BSD Medical Corporation, a developer and manufacturer of advanced medical systems that utilize heat therapy to treat cancer, announced today that a distinguished, international team of leading oncologists met in council while attending the May 2012 conference of the European Society for Radiotherapy and Oncology (ESTRO) in Barcelona, Spain.

2 Jun 2012

America's biopharmaceutical researchers work on many new approaches to fight cancer

America's biopharmaceutical research companies are testing 981 medicines and vaccines to fight the many types of cancer affecting millions of patients worldwide, according to a report released today by the Pharmaceutical Research and Manufacturers of America.

2 Jun 2012

CytRx INNO-206 doxorubicin conjugate shows anti-multiple myeloma effects

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that in animal and in vitro studies, its tumor-targeting doxorubicin conjugate INNO-206 showed anti-multiple myeloma effects and enhanced the anti-tumor effects of bortezomib, which is approved for the treatment of relapsed multiple myeloma.

30 May 2012

Polarization Gating Spectroscopy may detect pancreatic cancer

By simply shining a tiny light within the small intestine, close to that organ's junction with the pancreas, physicians at Mayo Clinic's campus in Florida have been able to detect pancreatic cancer 100 percent of the time in a small study.

22 May 2012

Cook Medical adds 25 gage needle to line of FNB histology portfolio

Cook Medical has added a 25 gage needle to its EchoTip ProCore line of fine needle biopsy (FNB) histology needles, which are designed for use in a procedure known as endoscopic ultrasound, or EUS. The EchoTip ProCore is a single-use, disposable needle for FNB intended for sampling of submucosal lesions, mediastinal masses, lymph nodes and intraperitoneal masses.

21 May 2012

Crownsville student receives Gordon E. Moore Award for pancreatic cancer test

Jack Andraka, 15, of Crownsville, Md. was awarded first place for his new method to detect pancreatic cancer at this year's Intel International Science and Engineering Fair, a program of Society for Science & the Public. Based on diabetic test paper, Jack created a simple dip-stick sensor to test blood or urine to determine whether or not a patient has early-stage pancreatic cancer.

19 May 2012

Viewpoints: VA failing to provide timely care; Roll up your sleeves to help fight AIDS; Primary care doctors' uncertain future

Those who have served know the military rules: Be on time, do it now. Once they file disability claims with the Department of Veteran Affairs, however, veterans wait, and wait longer…. Delay is not without consequences for the individual or the community…. We sent these young men and women off to battle. We owe them timely care.

19 May 2012

Pancreatic Cancer News and Research

Further Reading

Sun exposure, vitamin D and pancreatic cancer risk

Combination therapy may help defeat pancreatic cancer

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies

TGen, Scottsdale Healthcare open INNO-206 Phase 2 trial for pancreatic cancer

Prior chemotherapy extends postpalliative survival in pancreatic cancer

Azaya announces final results from ATI-1123 Phase I study on cancers

Study reveals mystery of how pancreatic cancer escapes immune detection

Patients with type 2 diabetes have 20% increased risk of blood cancers

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Antisense Pharma presents data from trabedersen Phase I/II cancer study at ASCO 2012

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

New data from OncoMed’s OMP-59R5 Phase I study on advanced solid tumors

Favorable results from CytRx’s INNO-206 Phase 1b/2 trial on soft tissue sarcomas

'Atzelberg Circle' researchers meet to advance hyperthermia as standard combination cancer therapy

America's biopharmaceutical researchers work on many new approaches to fight cancer

CytRx INNO-206 doxorubicin conjugate shows anti-multiple myeloma effects

Polarization Gating Spectroscopy may detect pancreatic cancer

Cook Medical adds 25 gage needle to line of FNB histology portfolio

Crownsville student receives Gordon E. Moore Award for pancreatic cancer test

Viewpoints: VA failing to provide timely care; Roll up your sleeves to help fight AIDS; Primary care doctors' uncertain future

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News